AstraZeneca PLC Net Worth
AstraZeneca PLC Net Worth Breakdown | AZN |
AstraZeneca PLC Net Worth Analysis
AstraZeneca PLC's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AstraZeneca PLC's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AstraZeneca PLC's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AstraZeneca PLC's net worth analysis. One common approach is to calculate AstraZeneca PLC's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AstraZeneca PLC's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AstraZeneca PLC's net worth. This approach calculates the present value of AstraZeneca PLC's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AstraZeneca PLC's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AstraZeneca PLC's net worth. This involves comparing AstraZeneca PLC's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AstraZeneca PLC's net worth relative to its peers.
Enterprise Value |
|
To determine if AstraZeneca PLC is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AstraZeneca PLC's net worth research are outlined below:
| AstraZeneca PLC ADR generated a negative expected return over the last 90 days | |
| AstraZeneca PLC ADR has 28.62 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC ADR has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AstraZeneca to invest in growth at high rates of return. | |
| AstraZeneca PLC ADR has a very strong financial position based on the latest SEC filings | |
| Latest headline from gurufocus.com: European Pharma Giants Face Challenges Amid U.S. Policy Shifts |
AstraZeneca PLC Quarterly Good Will |
|
AstraZeneca PLC uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AstraZeneca PLC ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AstraZeneca PLC's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
AstraZeneca PLC Target Price Consensus
AstraZeneca target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. AstraZeneca PLC's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most AstraZeneca analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand AstraZeneca stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of AstraZeneca PLC ADR, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAstraZeneca PLC Target Price Projection
AstraZeneca PLC's current and average target prices are 67.04 and 83.71, respectively. The current price of AstraZeneca PLC is the price at which AstraZeneca PLC ADR is currently trading. On the other hand, AstraZeneca PLC's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
AstraZeneca PLC Market Quote on 2nd of December 2024
Target Price
Analyst Consensus On AstraZeneca PLC Target Price
Know AstraZeneca PLC's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AstraZeneca PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AstraZeneca PLC ADR backward and forwards among themselves. AstraZeneca PLC's institutional investor refers to the entity that pools money to purchase AstraZeneca PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fisher Asset Management, Llc | 2024-09-30 | 10.5 M | Atlantic Trust Group, Llc | 2024-06-30 | 9.2 M | Blackrock Inc | 2024-06-30 | 7 M | Capital World Investors | 2024-09-30 | 6.3 M | Gqg Partners Llc | 2024-09-30 | 5.5 M | Jpmorgan Chase & Co | 2024-09-30 | 5.3 M | Neuberger Berman Group Llc | 2024-09-30 | 5.2 M | Ing Investment Management Llc | 2024-09-30 | 5 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 4.7 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 62.9 M | Primecap Management Company | 2024-09-30 | 42 M |
Follow AstraZeneca PLC's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 209.66 B.Market Cap |
|
Project AstraZeneca PLC's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.14 | 0.11 | |
| Return On Capital Employed | 0.12 | 0.11 | |
| Return On Assets | 0.06 | 0.10 | |
| Return On Equity | 0.15 | 0.14 |
When accessing AstraZeneca PLC's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AstraZeneca PLC's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AstraZeneca PLC's profitability and make more informed investment decisions.
Evaluate AstraZeneca PLC's management efficiency
AstraZeneca PLC ADR has Return on Asset of 0.085 % which means that on every $100 spent on assets, it made $0.085 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1666 %, implying that it generated $0.1666 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Return On Assets are very stable compared to the past year. As of the 2nd of December 2024, Asset Turnover is likely to grow to 0.79, while Total Current Assets are likely to drop about 15.3 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 25.06 | 26.31 | |
| Tangible Asset Value | 195.3 M | 185.6 M | |
| Tangible Book Value Per Share | (12.14) | (11.53) | |
| Enterprise Value Over EBITDA | 17.41 | 16.54 | |
| Price Book Value Ratio | 5.39 | 5.12 | |
| Enterprise Value Multiple | 17.41 | 16.54 | |
| Price Fair Value | 5.39 | 5.12 | |
| Enterprise Value | 233.7 B | 269 B |
Evaluating the management effectiveness of AstraZeneca PLC allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The AstraZeneca Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 4.5987 | Revenue 51.2 B | Quarterly Revenue Growth 0.18 | Revenue Per Share 2.7424 | Return On Equity 0.1666 |
AstraZeneca PLC Corporate Filings
6K | 20th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 28th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
AstraZeneca PLC Earnings Estimation Breakdown
The calculation of AstraZeneca PLC's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of AstraZeneca PLC is estimated to be 1.03685 with the future projection ranging from a low of 1.015 to a high of 1.07. Please be aware that this consensus of annual earnings estimates for AstraZeneca PLC ADR is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.01 Lowest | Expected EPS | 1.07 Highest |
AstraZeneca PLC Earnings Projection Consensus
Suppose the current estimates of AstraZeneca PLC's value are higher than the current market price of the AstraZeneca PLC stock. In this case, investors may conclude that AstraZeneca PLC is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and AstraZeneca PLC's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 10 | 78.06% | 0.4574 | 1.03685 | 2.08 |
AstraZeneca PLC Earnings History
Earnings estimate consensus by AstraZeneca PLC ADR analysts from Wall Street is used by the market to judge AstraZeneca PLC's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only AstraZeneca PLC's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.AstraZeneca PLC Quarterly Gross Profit |
|
AstraZeneca PLC Earnings per Share Projection vs Actual
Actual Earning per Share of AstraZeneca PLC refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering AstraZeneca PLC ADR predict the company's earnings will be in the future. The higher the earnings per share of AstraZeneca PLC, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.AstraZeneca PLC Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as AstraZeneca PLC, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of AstraZeneca PLC should always be considered in relation to other companies to make a more educated investment decision.AstraZeneca Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact AstraZeneca PLC's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | 1.04 | 0.4574 | -0.5826 | 56 | ||
2024-07-25 | 2024-06-30 | 1.2 | 0.99 | -0.21 | 17 | ||
2024-04-25 | 2024-03-31 | 1.22 | 1.03 | -0.19 | 15 | ||
2024-02-08 | 2023-12-31 | 0.79 | 0.73 | -0.06 | 7 | ||
2023-11-09 | 2023-09-30 | 0.85 | 0.87 | 0.02 | 2 | ||
2023-07-28 | 2023-06-30 | 0.95 | 1.08 | 0.13 | 13 | ||
2023-04-27 | 2023-03-31 | 1.07 | 0.96 | -0.11 | 10 | ||
2023-02-09 | 2022-12-31 | 0.67 | 0.69 | 0.02 | 2 | ||
2022-11-10 | 2022-09-30 | 0.72 | 0.84 | 0.12 | 16 | ||
2022-07-29 | 2022-06-30 | 0.77 | 0.86 | 0.09 | 11 | ||
2022-04-29 | 2022-03-31 | 0.83 | 0.95 | 0.12 | 14 | ||
2022-02-10 | 2021-12-31 | 0.73 | 0.84 | 0.11 | 15 | ||
2021-11-12 | 2021-09-30 | 0.62 | 0.54 | -0.08 | 12 | ||
2021-07-29 | 2021-06-30 | 0.43 | 0.45 | 0.02 | 4 | ||
2021-04-30 | 2021-03-31 | 0.75 | 0.82 | 0.07 | 9 | ||
2021-02-11 | 2020-12-31 | 0.68 | 0.54 | -0.14 | 20 | ||
2020-11-05 | 2020-09-30 | 0.44 | 0.47 | 0.03 | 6 | ||
2020-07-30 | 2020-06-30 | 0.44 | 0.48 | 0.04 | 9 | ||
2020-04-29 | 2020-03-31 | 0.47 | 0.53 | 0.06 | 12 | ||
2020-02-14 | 2019-12-31 | 0.59 | 0.45 | -0.14 | 23 | ||
2019-10-24 | 2019-09-30 | 0.45 | 0.5 | 0.05 | 11 | ||
2019-07-25 | 2019-06-30 | 0.3 | 0.37 | 0.07 | 23 | ||
2019-04-26 | 2019-03-31 | 0.42 | 0.45 | 0.03 | 7 | ||
2019-02-14 | 2018-12-31 | 0.76 | 0.79 | 0.03 | 3 | ||
2018-11-12 | 2018-09-30 | 0.4 | 0.35 | -0.05 | 12 | ||
2018-07-26 | 2018-06-30 | 0.3 | 0.35 | 0.05 | 16 | ||
2018-05-18 | 2018-03-31 | 0.34 | 0.24 | -0.1 | 29 | ||
2018-02-02 | 2017-12-31 | 0.47 | 0.65 | 0.18 | 38 | ||
2017-11-09 | 2017-09-30 | 0.55 | 0.56 | 0.01 | 1 | ||
2017-07-27 | 2017-06-30 | 0.42 | 0.44 | 0.02 | 4 | ||
2017-04-27 | 2017-03-31 | 0.4 | 0.5 | 0.1 | 25 | ||
2017-02-02 | 2016-12-31 | 0.59 | 0.61 | 0.02 | 3 | ||
2016-11-10 | 2016-09-30 | 0.74 | 0.66 | -0.08 | 10 | ||
2016-07-28 | 2016-06-30 | 0.76 | 0.83 | 0.07 | 9 | ||
2016-04-29 | 2016-03-31 | 0.48 | 0.48 | 0.0 | 0 | ||
2016-02-04 | 2015-12-31 | 0.44 | 0.47 | 0.03 | 6 | ||
2015-11-05 | 2015-09-30 | 0.77 | 0.52 | -0.25 | 32 | ||
2015-07-30 | 2015-06-30 | 0.51 | 0.6 | 0.09 | 17 | ||
2015-04-24 | 2015-03-31 | 0.53 | 0.54 | 0.01 | 1 | ||
2015-02-05 | 2014-12-31 | 0.43 | 0.38 | -0.05 | 11 | ||
2014-11-06 | 2014-09-30 | 0.52 | 0.53 | 0.01 | 1 | ||
2014-07-31 | 2014-06-30 | 0.55 | 0.65 | 0.1 | 18 | ||
2014-04-24 | 2014-03-31 | 0.62 | 0.59 | -0.03 | 4 | ||
2014-02-06 | 2013-12-31 | 0.61 | 0.62 | 0.01 | 1 | ||
2013-10-31 | 2013-09-30 | 0.63 | 0.61 | -0.02 | 3 | ||
2013-08-01 | 2013-06-30 | 0.58 | 0.6 | 0.02 | 3 | ||
2013-04-25 | 2013-03-31 | 0.67 | 0.71 | 0.04 | 5 | ||
2013-01-31 | 2012-12-31 | 0.7 | 0.78 | 0.08 | 11 | ||
2012-10-25 | 2012-09-30 | 0.74 | 0.76 | 0.02 | 2 | ||
2012-07-26 | 2012-06-30 | 0.68 | 0.77 | 0.09 | 13 | ||
2012-04-26 | 2012-03-31 | 0.89 | 0.91 | 0.02 | 2 | ||
2012-02-06 | 2011-12-31 | 0.78 | 0.81 | 0.03 | 3 | ||
2011-10-27 | 2011-09-30 | 0.84 | 0.86 | 0.02 | 2 | ||
2011-07-28 | 2011-06-30 | 0.91 | 0.87 | -0.04 | 4 | ||
2011-04-28 | 2011-03-31 | 1.08 | 1.12 | 0.04 | 3 | ||
2011-01-27 | 2010-12-31 | 0.67 | 0.7 | 0.03 | 4 | ||
2010-10-28 | 2010-09-30 | 0.75 | 0.75 | 0.0 | 0 | ||
2010-07-29 | 2010-06-30 | 0.8 | 0.9 | 0.1 | 12 | ||
2010-04-29 | 2010-03-31 | 0.86 | 1.01 | 0.15 | 17 | ||
2010-01-28 | 2009-12-31 | 0.76 | 0.71 | -0.05 | 6 | ||
2009-10-29 | 2009-09-30 | 0.69 | 0.84 | 0.15 | 21 | ||
2009-07-30 | 2009-06-30 | 0.7 | 0.82 | 0.12 | 17 | ||
2009-04-30 | 2009-03-31 | 0.7 | 0.79 | 0.09 | 12 | ||
2009-01-29 | 2008-12-31 | 0.58 | 0.63 | 0.05 | 8 | ||
2008-10-30 | 2008-09-30 | 0.57 | 0.66 | 0.09 | 15 | ||
2008-07-31 | 2008-06-30 | 0.54 | 0.63 | 0.09 | 16 | ||
2008-04-24 | 2008-03-31 | 0.6 | 0.64 | 0.04 | 6 | ||
2008-01-31 | 2007-12-31 | 0.47 | 0.55 | 0.08 | 17 | ||
2007-11-01 | 2007-09-30 | 0.46 | 0.52 | 0.06 | 13 | ||
2007-07-26 | 2007-06-30 | 0.52 | 0.6 | 0.08 | 15 | ||
2007-04-23 | 2007-03-31 | 0.51 | 0.51 | 0.0 | 0 | ||
2007-02-01 | 2006-12-31 | 0.48 | 0.47 | -0.01 | 2 | ||
2006-10-26 | 2006-09-30 | 0.49 | 0.51 | 0.02 | 4 | ||
2006-07-27 | 2006-06-30 | 0.47 | 0.51 | 0.04 | 8 | ||
2006-04-27 | 2006-03-31 | 0.4 | 0.45 | 0.05 | 12 | ||
2006-02-02 | 2005-12-31 | 0.37 | 0.39 | 0.02 | 5 | ||
2005-10-27 | 2005-09-30 | 0.33 | 0.38 | 0.05 | 15 | ||
2005-07-28 | 2005-06-30 | 0.28 | 0.38 | 0.1 | 35 | ||
2005-04-28 | 2005-03-31 | 0.29 | 0.32 | 0.03 | 10 | ||
2005-01-28 | 2004-12-31 | 0.29 | 0.3 | 0.01 | 3 | ||
2004-10-25 | 2004-09-30 | 0.26 | 0.28 | 0.02 | 7 | ||
2004-07-22 | 2004-06-30 | 0.24 | 0.25 | 0.01 | 4 | ||
2004-04-29 | 2004-03-31 | 0.27 | 0.24 | -0.03 | 11 | ||
2004-01-29 | 2003-12-31 | 0.2 | 0.19 | -0.01 | 5 | ||
2003-10-23 | 2003-09-30 | 0.17 | 0.24 | 0.07 | 41 | ||
2003-07-24 | 2003-06-30 | 0.17 | 0.2 | 0.03 | 17 | ||
2003-04-30 | 2003-03-31 | 0.21 | 0.27 | 0.06 | 28 | ||
2003-01-30 | 2002-12-31 | 0.21 | 0.23 | 0.02 | 9 | ||
2002-10-24 | 2002-09-30 | 0.18 | 0.2 | 0.02 | 11 | ||
2002-07-25 | 2002-06-30 | 0.24 | 0.23 | -0.01 | 4 | ||
2002-04-26 | 2002-03-31 | 0.24 | 0.28 | 0.04 | 16 | ||
2002-01-31 | 2001-12-31 | 0.23 | 0.89 | 0.66 | 286 | ||
2001-10-24 | 2001-09-30 | 0.21 | 0.24 | 0.03 | 14 | ||
2001-07-26 | 2001-06-30 | 0.21 | 0.21 | 0.0 | 0 | ||
2001-02-08 | 2000-12-31 | 0.21 | 0.21 | 0.0 | 0 | ||
2000-10-25 | 2000-09-30 | 0.23 | 0.19 | -0.04 | 17 | ||
1999-10-29 | 1999-09-30 | 0.17 | 0.19 | 0.02 | 11 | ||
1999-08-09 | 1999-06-30 | 0.24 | 0.41 | 0.17 | 70 | ||
1999-02-17 | 1998-12-31 | 0.24 | 0.25 | 0.01 | 4 |
AstraZeneca PLC Corporate Directors
| Marc Dunoyer | Chief Financial Officer, Executive Director | Profile | |
| Sherilyn McCoy | Non-Executive Independent Director | Profile | |
| Genevieve Berger | Non-Executive Independent Director | Profile | |
| Nazneen Rahman | Non-Executive Independent Director | Profile |
Already Invested in AstraZeneca PLC ADR?
The danger of trading AstraZeneca PLC ADR is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AstraZeneca PLC is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AstraZeneca PLC. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AstraZeneca PLC ADR is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.034 | Dividend Share 2.97 | Earnings Share 2.08 | Revenue Per Share 2.7424 | Quarterly Revenue Growth 0.18 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.